AlidaBio provides the EpiPlex platform, a proximity‑barcoding workflow that simultaneously detects m6A, inosine, and pseudouridine alongside whole‑transcriptome expression from low‑input or degraded RNA samples such as FFPE and liquid biopsies. The solution is offered as a turnkey service or in‑lab kits, with machine‑learning‑driven EpiScout software delivering normalized quantification, quality metrics, and visual reports in a single, seven‑hour workflow.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OFounders
Product
Problem
Researchers lack a unified, efficient method to profile multiple RNA modifications such as m6A, inosine, and pseudouridine alongside gene expression, especially from low‑input or clinically derived samples like FFPE or liquid biopsies. Existing workflows are fragmented, require large inputs, and involve complex library preparation and data analysis, limiting throughput and reproducibility.
Solution
AlidaBio offers the EpiPlex platform, a turnkey solution that combines proximity‑barcoding chemistry with engineered protein binders to enrich and encode RNA modifications into sequencing‑compatible barcodes. The workflow accepts as little as 20 ng poly(A) RNA or 250 ng total RNA, works with degraded clinical specimens, and generates sequencing‑ready libraries in about seven hours. Users can choose Uni‑Mod, Duo‑Mod, or Tri‑Mod services to profile one, two, or three modifications in a single assay, while simultaneously capturing whole‑transcriptome expression. Raw sequencing data are processed by the EpiScout analysis pipeline, which applies machine‑learning peak calling and spike‑in normalization to deliver relative quantification, quality metrics, and visual reports. The same platform is available as a fully managed service or as in‑lab kits with optional compute tokens for cloud‑based analysis.
Target Audience
Primary customers are academic and industry researchers studying epitranscriptomic regulation in disease, drug discovery, and biomarker development, particularly those working with limited or clinical RNA samples.
Features
- Proximity‑barcoding assay that converts m6A, inosine, and pseudouridine into distinct NGS barcodes for multiplexed detection
- Engineered protein binders (8× smaller than antibodies) provide high specificity and low background enrichment
- Low‑input compatibility (20 ng poly(A) or 250 ng total RNA) suitable for FFPE, liquid biopsy, and other clinical samples
- Integrated spike‑in controls enable relative quantification and cross‑sample comparability
- Single‑run workflow produces both modification maps and whole‑transcriptome expression data
- EpiScout software delivers machine‑learning‑based peak calling, QC metrics, and publication‑ready visualizations via a DNAnexus cloud app or compute token
- End‑to‑end service options (Uni‑Mod, Duo‑Mod, Tri‑Mod) with same platform and analysis pipeline